Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

H0165

Sigma-Aldrich

7-Ethyl-10-hydroxycamptothecin

powder, ≥98% (HPLC)

Synonym(s):

SN-38

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C22H20N2O5
CAS Number:
86639-52-3
Molecular Weight:
392.40
MDL number:
MFCD00871873
UNSPSC Code:
12352204
PubChem Substance ID:
329815105
NACRES:
NA.77

product name

7-Ethyl-10-hydroxycamptothecin, ≥98% (HPLC), powder

biological source

Artemisia annua

Assay

≥98% (HPLC)

form

powder

solubility

DMSO: 1 mg/mL

storage temp.

−20°C

SMILES string

OC1=CC2=C(CC)C(C3)=C(N=C2C=C1)C(N3C4=O)=CC5=C4COC([C@]5(O)CC)=O

InChI

1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1

InChI key

FJHBVJOVLFPMQE-QFIPXVFZSA-N

Application

7-Ethyl-10-hydroxycamptothecin has been used:
  • to inhibit enterovirus 71 (EV71) (H) infection
  • to screen the chemosensitivity of pancreatic adenocarcinoma cells
  • as a chemical to study its ability to reverse multidrug resistance (MDR), due to ATP binding cassette (ABC) transporters

Biochem/physiol Actions

Active metabolite of irinotecan. Inhibitor of topoisomerase I.. Gene expression analysis of colon cancer cell lines treated with SN-38 showed differential effects: the majority of affected genes were down-regulated (including, most strongly, genes related to receptor and kinase activity, signal transduction, apoptosis, RNA processing, protein metabolism and transport, cell cycle and transcription. Some of the up-regulated genes were involved in apoptosis, transcription, development and differentiation.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H360D,H372

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B - STOT RE 1

Target Organs

Gastro-intestinal system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mélanie Rouleau et al.
Molecular pharmacology, 85(1), 29-36 (2013-10-22)
Transcripts of the UGT1A gene, encoding half of human UDP-glucuronosyltransferase (UGT) enzymes, undergo alternative splicing, resulting in active enzymes named isoforms 1 (i1s) and novel truncated isoforms 2 (i2s). Here, we investigated the effects of depleting endogenous i2 on drug
Shuichi Hironaka et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4438-4444 (2013-11-06)
This phase III study compared treatment with weekly paclitaxel and biweekly irinotecan in patients with advanced gastric cancer refractory to treatment with fluoropyrimidine plus platinum. Patients were randomly assigned to receive either paclitaxel (80 mg/m(2) on days 1, 8, and
Josep Tabernero et al.
European journal of cancer (Oxford, England : 1990), 50(2), 320-331 (2013-10-22)
The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the
Kan Xing Wu et al.
Antiviral research, 143, 122-133 (2017-04-22)
Enterovirus 71 (EV71) is one of the causative agents of hand, foot and mouth disease (HFMD) associated with severe neurological disease. EV71's pathogenesis remains poorly understood and the lack of approved antiviral has led to its emergence as a clinically
Atish Patel et al.
Pharmacological research, 121, 184-193 (2017-04-30)
Cancer is a disease whose treatment is often limited due to the development of a phenomenon known as multidrug resistance (MDR). There is an immense demand for development of novel agents that can overcome the MDR in cancer. A group
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service